Last reviewed · How we verify
Linezolid (L)
Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Vancomycin-resistant Enterococcus faecium (VRE) infections, Methicillin-resistant Staphylococcus aureus (MRSA) infections, Nosocomial pneumonia.
At a glance
| Generic name | Linezolid (L) |
|---|---|
| Sponsor | Shenzhen Third People's Hospital |
| Drug class | Oxazolidinone antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Linezolid is an oxazolidinone antibiotic that binds to the bacterial 50S ribosomal subunit and blocks the initiation of protein synthesis. This mechanism is bacteriostatic, halting bacterial growth and allowing the immune system to clear the infection. It is effective against both gram-positive and gram-negative bacteria, including resistant strains such as MRSA and VRE.
Approved indications
- Vancomycin-resistant Enterococcus faecium (VRE) infections
- Methicillin-resistant Staphylococcus aureus (MRSA) infections
- Nosocomial pneumonia
- Complicated skin and soft tissue infections
- Community-acquired pneumonia
Common side effects
- Thrombocytopenia
- Anemia
- Nausea
- Diarrhea
- Headache
- Peripheral neuropathy
- Optic neuropathy
Key clinical trials
- Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment (PHASE4)
- A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets (PHASE2)
- Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis (NA)
- A PAN-USR TB Multi-Center Trial (PHASE3)
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB (PHASE2)
- 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province (NA)
- A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB (PHASE3)
- Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Linezolid (L) CI brief — competitive landscape report
- Linezolid (L) updates RSS · CI watch RSS
- Shenzhen Third People's Hospital portfolio CI